![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study of Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs: Week 96 Update
By
ASCO 2022 Conference Coverage
FEATURING
Jorge Cortés
By
ASCO 2022 Conference Coverage
FEATURING
Jorge Cortés
22 views
July 12, 2022
Comments 0
Login to view comments.
Click here to Login
Leukemia